1534P First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC): Safety run-in results from the phase III LEAP-014 study
J-M. Sun(Samsung Medical Center), Lin Shen(Peking University), Chin‐Yo Lin(University of Houston), Y. Zhang(Harbin Medical University), Fernando Rivera(Marqués de Valdecilla University Hospital), C. Rojas, M-H. Chen, Sukrut Shah(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dora L.�W. Kwong(University of Hong Kong), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Shigehiro Yamamoto(National Cancer Center Hospital East), Lei Yu(Taiyuan Central Hospital)
Cited by 5
Related Papers
MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma
|JAMA|2008|1.6k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k